CTLA4 and neoplasm: developed CTLA-4-siRNA loaded PLGA nanoparticles to successfully deliver CTLA-4-siRNA into both CD4 + and CD8 + T cell subsets at the tumor sites, thereby down-regulating CTLA-4 in activated T cells and enhancing anti-tumor immune responses [348].